Amarin Corp Plc (AMRN)

[BioChica]

The question? Actually combined both. They should be voted separately.

2.
VOTE:
Taking into account the described efficacy and safety data for Vascepa, do you believe that its effects on the described lipid/lipoprotein parameters are sufficient to grant approval
for co
-
administration with statin therapy for the treatment of patients with mixed dyslipidemia and CHD or CHD risk equivalent prior to the completion of REDUCE
-
IT?
Please provide the rationale underlying your recommendation.